Early subclinical inflammation in kidney transplants is associated with later graft fibrosis and
dysfunction. Regulatory T cells (Tregs) can reverse established inflammation in animal
models. We conducted a pilot safety and feasibility trial of autologous Treg cell therapy in
three kidney transplant recipients with subclinical inflammation noted on 6-month
surveillance biopsies. Tregs were purified from peripheral blood and polyclonally expanded
ex vivo using medium containing deuterated glucose to label the cells. All patients received …